Jan de Witte - 16 Nov 2022 Form 4 Insider Report for RESMED INC (RMD)

Reporting relationship: Director
Issuer ticker: RMD
Reported as of: 16 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Nov 2022, 15:33:52 UTC
Prior SEC filing: 03 Nov 2022
Next SEC filing: 19 Jan 2023
Source filing: View source filing
Reporting owner signature: Jan De Witte, director

Key filing fact

Jan de Witte filed Form 4 for RESMED INC (RMD) on 21 Nov 2022.

Key facts

This page summarizes Jan de Witte's Form 4 filing for RESMED INC (RMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Nov 2022, 15:33.

Change

Previous filing in this sequence was filed on 03 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RMD transaction

ReMed Common Stock

Award

Transaction value: $0
Shares: +1,122
Change %: +22%
Price: $0.000000
Shares after: 6,111
Date: 16 Nov 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2023, or the annual shareholders meeting in the year following the grant date.